Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

NCT02199665 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02199665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02199665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Completed
Start date
June 12, 2014
Completion date
October 25, 2025
Enrollment
52 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma